BeOne Medicines (ONC) Cash from Operations (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Cash from Operations of 201336000.0 for Q1 2026, up 356.73% year-over-year from 44082000.0 in Q1 2025, and down 51.76% quarter-over-quarter from 417347000.0 in Q4 2025.
BeOne Medicines (ONC) Cash from Operations (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Cash from Operations for 12 consecutive years, with 201336000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 356.73% year-over-year to 201336000.0; the TTM figure through Mar 2026 stood at 1284834000.0 (up 505.99% YoY), while the FY2025 annual figure was 1127580000.0, up 901.8% from the prior year.
- Cash from Operations slipped to 201336000.0 in Q1 2026 per ONC's latest filing, from 417347000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 417347000.0 in Q4 2025 and bottomed at 563777000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 86222764.71 across 5 years, with a median of 95588000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 350.36% — and 2025, when it soared 455.28%.
- BeOne Medicines' Cash from Operations stood at 318191000.0 in 2022, then soared by 30.34% to 221638000.0 in 2023, then soared by 133.91% to 75160000.0 in 2024, then jumped by 455.28% to 417347000.0 in 2025, then sank by 51.76% to 201336000.0 in 2026.
- Business Quant data shows ONC's Cash from Operations at 201336000.0 in Q1 2026, 417347000.0 in Q4 2025, and 402553000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 462.82 Mn |
| Jun 30, 2026 | 462.82 Mn |
| Mar 31, 2026 | 201.34 Mn |
| Mar 31, 2026 | 201.34 Mn |
| Dec 31, 2025 | 417.35 Mn |
| Dec 31, 2025 | 417.35 Mn |
| Sep 30, 2025 | 402.55 Mn |
| Sep 30, 2025 | 402.55 Mn |
| Jun 30, 2025 | 263.60 Mn |
| Jun 30, 2025 | 263.60 Mn |
| Mar 31, 2025 | 44.08 Mn |
| Mar 31, 2025 | 44.08 Mn |
| Dec 31, 2024 | 75.16 Mn |
| Dec 31, 2024 | 75.16 Mn |
| Sep 30, 2024 | 188.37 Mn |
| Sep 30, 2024 | 188.37 Mn |
| Jun 30, 2024 | -95.59 Mn |
| Jun 30, 2024 | -95.59 Mn |
| Mar 31, 2024 | -308.57 Mn |
| Mar 31, 2024 | -308.57 Mn |